Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

FHS
May 30, 2024
9:17 am

In this Interview, NewsMedical speaks with Amy Landreman about NanoBRET® Technology and its role in cellular target engagement.

Q&A: Atsena Therapeutics’ gene therapy for inherited blindness shows promise

Seven years after the FDA approved Luxterna, scientists have yet to bring another congenital blindness treatment to the market. A team of researchers from the

September 10, 2024

New guidance balances GLP-1 risks and benefits for surgery

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new clinical

October 30, 2024

Tumor microbiomes offer new insights for enhancing cancer therapies

Comprehensive review reveals the significant impact of tumor-resident bacteria on metastatic cancer, showing how microbiome genomes influence tumor biology, immune system response, and treatment effectiveness.

April 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.